The researchers suggested that Ashkenazi Jewish women as well as women of other ancestries might benefit from broader genetic screening for breast cancer risk.
Researchers shored up their age-specific breast and ovarian cancer risk estimates by following thousands of individuals with pathogenic BRCA1/2 mutations.
The first randomized study to show a PARP inhibitor benefits advanced breast cancer patients is also a sign of the expanding utility of BRCA testing in precision medicine.
The firm will use machine learning and bioinformatics, and will generate new genomic data to help improve and personalize treatment of BRCA mutation carriers.
The analysis from Quest Diagnostic researchers compared the cost-effectiveness of a seven-gene panel test to BRCA1 and BRCA2 testing alone in improving life expectancy.
Using a new mathematical model, researchers uncovered mutational signatures related to homologous recombination deficiency in up to one-fifth of breast cancers.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
